Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2009

View Archived Issues

Amantadine improves tardive dyskinesia in schizophrenia patients

Cytokine starts phase I study of oral CPSI-2364, a chemically modified semapimod

LX-1032 receives EMEA orphan drug designation for carcinoid syndrome

Florpiramine F 18 displays potential utility as an imaging biomarker in AD; phase II data disclosed

Foresight reports results from a pilot study of FST-100 in viral conjunctivitis

Compugen reports effects of novel peptide in animal model of retinopathy

Phase III lubiprostone results released for opioid-induced bowel dysfunction

FDA grants approval to ViroMed for phase II clinical trial of VM-202

Histamine antagonist PF-03654746 under development as treatment for AD; phase I data presented

AZD-3480 fails to meet primary outcome in phase IIb trial in mild to moderate AD

Distinct mechanism of action of chimeric variants of the anti-TLR-2 antibody OPN-301 disclosed

CCR2-targeting fusion protein CCL2-LPM developed for the treatment of autoimmune conditions

Actelion describes novel lipoxin receptor agonists

Korea Institute of Science and Technology claims biosynthesized compounds

AVEO and OSI expand drug discovery and translational research collaboration in cancer

Amgen describes novel TRPM8 ligands for the treatment of pain and other diseases

Novel 11beta-HSD1 inhibitors claimed by Vitae Pharmaceuticals for the treatment of diabetes

Concert Pharmaceuticals patents orexin receptor antagonists for the treatment of sleep disorders

FDA approves Incyte's SPA for phase III trial of INCB-18424 in myelofibrosis

Novavax selects RSV vaccine candidate for additional preclinical studies to support IND

Poniard reports results from phase I cardiac safety study of chemotherapy agent picoplatin

FoldRx reports preliminary results from phase II/III clinical study of tafamidis

Bayer and Onyx report results from phase II trial of Nexavar and capecitabine in breast cancer

Critical Outcome Technologies initiates drug discovery program for Alzheimer's disease

Living Cell initiates phase I/IIa clinical trial of diabetes drug DiabeCell

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...